The Role of NaV1.8 in Human Pain Models
This study aims to understand how NaV1.8, a specific type of sodium channel found in peripheral nerves, contributes to different types of pain in humans. To address this, suzetrigine, a highly selective blocker of the NaV1.8 channel, is used. While current pain medications often have side effects that limit their use,
| Condition(s) | Pain, Acute Pain, Healthy Volunteer Study |
|---|---|
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Study type | Interventional |
| Summary | This study aims to understand how NaV1.8, a specific type of sodium channel found in peripheral nerves, contributes to different types of pain in humans. To address this, suzetrigine, a highly selective blocker of the NaV1.8 channel, is used. While current pain medications often have side effects that limit their use, NaV1.8 is a promising target for new, non-opioid pain treatments because it is primarily located in the nerves that send pain signals to the brain. This study is a randomised, placebo-controlled double-blind crossover microdosing trial. This means that very small, safe amounts of the drug are injected directly into the skin of healthy volunteers to observe its effects locally. This approach ensures the drug works only at the injection site with negligible exposure to the rest |
| Who can participate | Inclusion criteria * Age between 18 and 70 years * Full legal capacity Exclusion criteria * Participant of another study, ongoing or within the last 4 weeks * Medication intake (except contraception) or drug abuse * Female subjects: Positive pregnancy test or breastfeeding * Verified body temperature above 38°C * Known allergic diseases, in particular asthmatic disorders * Limited accessibility of forearms (e.g. orthopedic cast) * Sensory deficit, skin disease or hematoma at the forarms |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Medical University of Vienna |
| Locations | Vienna, State of Vienna, Austria |
| Start date | 2026-04-21 |
| NCT ID | NCT07511400 |
| Official listing | https://clinicaltrials.gov/study/NCT07511400 |